| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 336.3 | 274.1 |
| Gross profit | 172.5 | 151.6 |
| Net income | 25.3 | 42.2 |
| EPS (diluted, $ a share) | $0.53 | $0.86 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -40.1% |
|---|---|
| Revenue, year on year | +22.7% |
| Gross margin | 51.3% |
| Operating margin | 24.0% |
10-Q filed with the SEC, NYSE: PBH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Prestige Consumer Healthcare Inc.: key numbers
- Share price
- $48.00Close, Nov 16
- Market cap
- $2.28B
- Shares outstanding
- 47.4MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Prestige Consumer Healthcare Inc.
All →Prestige Consumer Healthcare Financial Results
Prestige Consumer Healthcare reported Q2 fiscal 2027 revenue of $336.3 million, a 22.7% increase driven by the acquisitions of Breathe Right and LaCorium. Adjusted diluted EPS rose to $1.13 from $1.07 in the prior year, supported by strong consumption across eCommerce channels. The company adjusted its full-year revenue guidance to a range of $1.28 billion to $1.29 billion.
- Term
- Q2 2027
“We were pleased with our second quarter and first half revenue and EPS performance, driven by continued strength in our leading brands and strong early contributions from the Breathe Right® portfolio and LaCorium acquisitions that closed in June and July, respectively. Our portfolio performed in line with our expectations, with strong consumption growth across channels including eCommerce. This translated into strong mid-single-digit earnings growth and sets us up for continued strong free cash flow moving forward.”
Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare